Regeneron Pharmaceuticals said Monday it will pay $800 million to Alnylam, a biotechnology firm in Cambridge, Mass., to leverage its gene-silencing technique for the development of new therapies and to become its exclusive partner for new drugs focused on the central nervous system or the eye.

“It’s about the future, and it’s about synergies,” George Yancopoulos, Regeneron’s chief scientific officer and co-founder, said in an interview. “We’re not going to be making the standard deals where companies are just hoping to acquire an asset. We’re going to do the opposite. We’re looking for people with which we can do greater things together.”

Unlock this article by subscribing to STAT Plus and enjoy your first 30 days free!


What is it?

STAT Plus is a premium subscription that delivers daily market-moving biopharma coverage and in-depth science reporting from a team with decades of industry experience.

What's included?

  • Authoritative biopharma coverage and analysis, interviews with industry pioneers, policy analysis, and first looks at cutting edge laboratories and early stage research
  • Subscriber-only networking events and panel discussions across the country
  • Monthly subscriber-only live chats with our reporters and experts in the field
  • Discounted tickets to industry events and early-bird access to industry reports

Leave a Comment

Please enter your name.
Please enter a comment.

Sign up for our Daily Recap newsletter

A roundup of STAT’s top stories of the day in science and medicine

Privacy Policy